Senolytic CAR T cells dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Living immune cells, called T cells, engineered to find and kill worn-out 'zombie' cells by a marker on their surface called uPAR. Every result is in mice. No human study of this for ageing or zombie cells is registered anywhere.
Evidence grade for Senolytic CAR T cells: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 3 animal studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 animal studies, no human study
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism, Muscle and strength, Ageing and longevity
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
These are immune cells built in a lab to hunt worn-out 'zombie' cells. They find them by a marker on the cell surface. This is mouse research. It is not a product.
What people take it for
- Clearing zombie cells to slow ageing.
- One treatment that keeps working, instead of repeat pills.
What studies in people showed
Nobody has tested it in people for ageing, and no study is registered. In mice, the cells cleared zombie cells and eased liver scarring. One dose helped old mice exercise more and handle blood sugar better. At higher doses, the cells were toxic to mice. The same kind of cell therapy in cancer patients needs chemo first and carries serious warnings.
What people report
Reports, not study results
The good
- We have not collected user reports on this one. Nobody can get it.
The bad
- In mice, higher doses were toxic.
- The approved cell therapies of this kind for cancer carry the FDA's strongest warnings, for a dangerous immune overreaction, nerve problems and new cancers.
Where these come from: The bad lines are from the mouse work and the cancer drug warnings on this page. We have not collected user reports on this one, because nobody can get it.
My bottom line
Clever science, all in mice. Nobody can buy this, and anyone who says they sell it is not selling this. Train, eat protein and check your blood work while the science catches up.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Living longer1 animal or lab study
- Lasting longer, stamina1 animal or lab study
- Blood sugar and insulin1 animal or lab study
33 of the 36 indexed goals have no study of any kind behind Senolytic CAR T cells
No study in people, animals or cells on this page reports a result for these. That does not prove Senolytic CAR T cells does nothing for them. It does mean anything you have heard about Senolytic CAR T cells and one of these did not come from a study cited here.
Show full evidence
What is Senolytic CAR T cells?
Living immune cells, called T cells, engineered to find and kill worn-out 'zombie' cells by a marker on their surface called uPAR. Every result is in mice. No human study of this for ageing or zombie cells is registered anywhere.
This is one of the cleverest ideas in the senolytic field, and it has never been given to a person for this purpose.
Senolytic pills work by pushing already-stressed zombie cells over the edge so they die. That means they are only as choosy as the survival switch they block. This approach flips the problem. Instead of finding a drug zombie cells cannot survive, find a protein that sits on their surface. Then build an immune cell that hunts it.
The protein is uPAR. In 2020 researchers found that it turns up on the surface of zombie cells across many kinds of cell ageing. T cells fitted with a man-made sensor for uPAR, called a CAR, cleared zombie cells in a dish and in mice. In mice with lung cancer treated with a drug pair that turns cells into zombie cells, the mice lived longer. In mice with liver scarring caused by chemicals or diet, the liver tissue went back toward normal. The 2020 paper in Nature has a published correction from 2024.
A 2024 follow-up in mice found something important. A single dose gave long-lasting benefit. Normally ageing mice could exercise more, and old mice and mice on a high-fat diet handled blood sugar better. If that holds, a living cell therapy that stays in the body would avoid the repeat dosing that every senolytic pill needs.
All of that is mice. CAR T therapy in people is not gentle. The approved products for blood cancer need chemotherapy first to make room for the new cells. They carry the FDA's strongest warning, a boxed warning, for a dangerous immune overreaction, nerve and brain problems, and since 2024 for new T cell cancers. uPAR is not found only on zombie cells, and the 2020 work itself found these cells were toxic to mice at higher doses. Nobody has shown this can be made safe enough for a healthy older person.
How does Senolytic CAR T cells work?
uPAR is a protein anchored on the outside of cells. It goes up a lot when cells turn into zombie cells, so it can serve as a tag for them. A CAR is a man-made protein spliced into a T cell. It lets the T cell spot that tag directly and kill whatever carries it. Because the killer is a living cell that multiplies when it meets its target, one dose could in theory keep working. That is the big difference from a pill the body clears in hours. The same thing is the risk. An immune cell tuned to a tag that healthy tissue also carries, at lower levels, does not stop when the zombie cells are gone.
The state of the research
There is no human evidence of any kind for senolytic CAR T cells in ageing. A registry search finds no study of it for ageing or zombie cells. Every registered study that uses the word senolytic is a pill or a supplement.
That matters more than usual here. The gap between the biology and the clinic is not just a lack of money for a study. CAR T is made from each patient's own cells and costs hundreds of thousands of dollars per person. It needs chemotherapy first and a hospital stay to watch for a dangerous immune overreaction. Giving that to someone who is not ill, to clear cells whose removal has never been shown to help a person, is a trade nobody has made work even on paper. The published path forward is to find a better tag for zombie cells, not to put the current version into people.
Senolytics are drugs meant to clear out worn-out 'zombie' cells, called senescent cells. No senolytic of any kind has yet made people better off in a proper human study against a dummy treatment. That is the most useful fact to carry into any senolytic talk. One pair, dasatinib plus quercetin, has lowered the number of zombie cells in people, measured in skin and fat samples. What has not followed is a study where people who got a senolytic walked further, broke fewer bones or lived longer than people who did not. The two studies against a dummy that tried, one in lung scarring (pulmonary fibrosis) and one on bone turnover after menopause, found no difference.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 3 animal studies. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 3 sources here are studies in people.
- Animal study · done in animals3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2020 and 2024.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not applicable in the usual sense. This is a living cell product that expands on meeting its target and persists, so exposure is governed by the survival of the engineered cells rather than by drug clearance.
No amino acid sequence is on file for Senolytic CAR T cells, so none is drawn rather than guessed from a name.
The studies we cite
- Animal study2020Senolytic CAR T cells reverse senescence-associated pathologies
In mice and in a dish. Researchers found uPAR on the surface of zombie cells and built T cells to hunt it. The cells cleared zombie cells, helped mice with lung cancer live longer, and eased liver scarring in mice. This paper was later corrected.
Mouse and in vitro. Identified uPAR as a cell-surface protein broadly induced during senescence, and showed that uPAR-specific CAR T cells ablated senescent cells in vitro and in vivo, extended survival of mice with lung adenocarcinoma treated with a senescence-inducing drug combination, and restored tissue homeostasis in mice with chemically or diet-induced liver fibrosis. This paper carries a published Author Correction, cited below.
- Animal study2024Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
In mice. A single dose of the uPAR-hunting T cells helped normally ageing mice exercise more. It helped old mice and mice on a high-fat diet handle blood sugar better. The effect lasted, and it also worked as prevention.
Mouse. uPAR-positive senescent cells accumulate with age and were targetable with senolytic CAR T cells. A single administration improved exercise capacity in physiologically ageing mice and ameliorated metabolic dysfunction, including glucose tolerance, in aged and high-fat-diet mice, with long-lasting therapeutic and preventive effect.
- Animal study2024Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies
The published correction to the 2020 Nature paper. It is listed so you know the first report was changed after it came out.
The published correction to the 2020 Nature paper. Cited here so readers know the primary report was amended rather than left as first published.
Common questions
Has Senolytic CAR T cells been tested in people?
Not in any study cited here. Living immune cells, called T cells, engineered to find and kill worn-out 'zombie' cells by a marker on their surface called uPAR. Every result is in mice. No human study of this for ageing or zombie cells is registered anywhere.
What is the Senolytic CAR T cells dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 3 animal studies, no human study
Is Senolytic CAR T cells FDA-approved?
No CAR T product that clears worn-out (senescent) cells is approved, and none is in a registered human trial for ageing or worn-out cells. CAR T therapy in general is approved in the United States for certain blood cancers. That is a different target, a different patient and a different weighing of risk.
Can I get senolytic CAR T therapy?
No. It does not exist as a product, and there is no study to join. Any clinic selling a senolytic cell therapy is not selling this.
What does it actually do?
In mice: it clears zombie cells that carry uPAR, eases liver scarring, and helps old mice exercise more and handle blood sugar better, all from a single dose. In people: nothing has been tested.
Why is it more interesting than dasatinib or fisetin?
Two reasons. It targets a marker on the cell surface instead of relying on zombie cells being fragile. And because the T cells stay in the body, one dose kept working in mice. Senolytic pills are given in repeated bursts because the body clears them within hours.
How dangerous is CAR T?
In cancer it is a serious hospital treatment. The approved products need chemotherapy first. They carry boxed warnings, the FDA's strongest, for a dangerous immune overreaction, nerve and brain problems and, since 2024, new T cell cancers. uPAR is also found on some healthy cells, and the original mouse work found toxicity at higher cell doses.
Is the research trustworthy?
It is published in Nature and Nature Aging, and other groups have built on it. The 2020 paper does have a published correction, which we cite directly instead of leaving it out.